Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eladynos

Biogen Idec building

Biogen Idec wins EU battle on Tecfidera exclusivity

Oral MS drug gains New Active Substance status

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

- PMLiVE

CHMP names France’s Pierre Demolis vice-chair

He is director of the oncology and haematology division at the ANSM

- PMLiVE

Amgen buys total filgrastim rights from Roche

Wrests control of white blood cell stimulator franchise

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

AZ/Amgen report positive data with psoriasis antibody

Brodalumab shows efficacy in achieving and maintaining clear skin

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

Roche - Basel

Roche’s Kadcyla and Bayer’s Xofigo near EU approval

Cancer drugs receive CHMP backing

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

Amgen drug misses endpoint in acute heart failure trial

Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure

- PMLiVE

Amgen and Onyx agree $10.4bn takeover deal

Deal provides indication of the premium big biopharma will pay to replenish pipelines

- PMLiVE

Amgen buys US rights to Servier’s Procoralan

Also obtains option to develop S38844 while Servier has option to commercialise omecamtiv mecarbil in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links